David Hyman, MD
David Hyman is the Chief of the Early Drug Development Service and Co-Chair of the Center for Mechanism Based Therapy (CMBT) at Memorial Sloan Kettering Cancer Center in New York City. Dr. Hyman’s personal research has focused on the development of genomically selected targeted cancer therapy. In particular, he has helped to pioneer the use of multi-histology, genomically selected, “basket” studies which treat patients based on the mutations present rather than where the cancer originated in the body. Dr. Hyman’s translational research is focused on understanding how the consequences of target pathway inhibition varies as a function of tumor cell lineage, gene dosage and clonality, and the complement of concurrent genetic alterations within the tumor cell. Dr. Hyman also serves as the author and Principal Investigator of Memorial Sloan Kettering’s institutional cancer genomics protocol that has consented 40,000 patients and continues to play a foundational role in all facets of cancer genomics research at the center.
Dr. Hyman pioneered the development of (and became the inaugural Chief of) the Early Drug Development Service at Memorial Sloan Kettering. Under his leadership, the Early Drug Development Service has become an international academic leader in drug development. Dr. Hyman has published extensively on the design and conduct of early phase clinical trials as well as precision medicine and basket studies in multiple top clinical and scientific journals including the New England Journal of Medicine (NEJM), Nature, Cell, Science, Journal of Clinical Oncology (JCO), Cancer Discover, JAMA, JAMA Oncology, and others. In 2015, Dr. Hyman published the first-in-kind basket study that evaluated vemurafenib in BRAF-mutant cancers in the NEJM. Data from this study was subsequently used to support a supplemental new drug application by the FDA. In 2018, Dr. Hyman published the results of another pivotal basket study evaluating the efficacy of a novel drug called larotrectinib in TRK-fusion positive cancers also in the NEJM. The study defined larotrectinib as the first targeted therapy with efficacy regardless of tumor type and is expected to support global regulatory approval of this drug this year. Dr. Hyman serves on multiple national and international leadership committees with the American Association of Clinical Oncology (ASCO), the American Association of Cancer Researchers (AACR), and the European Association of Medical Oncology (ESMO). He has received leadership awards, including from the National Cancer Institute, and serves as Senior Editor at Clinical Cancer Research.